Update on disease-modifying treatments for multiple sclerosis

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 1938-1945

  Carrithers, Michael D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

fumarate; glatiramer; immune therapy; interferon; multiple sclerosis; natalizumab

Indexed keywords

ALEMTUZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; NATALIZUMAB; RITUXIMAB; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TOLUIDINE DERIVATIVE;

DISEASE ACTIVITY; HUMAN; MEDLINE; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; QUALITY OF LIFE; RELAPSE; REVIEW; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROTONATES; DIMETHYL FUMARATE; FINGOLIMOD HYDROCHLORIDE; GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; QUALITY OF LIFE; RITUXIMAB; TOLUIDINES; TREATMENT OUTCOME;

EID: 84908536431     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.08.006     Document Type: Review

References (65)

1. G. Kobelt, J. Berg, D. Atherly, and O. Hadjimichael Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States Neurology 66 2006 1696 1702
2. A. Scalfari, V. Knappertz, and G. Cutter Mortality in patients with multiple sclerosis Neurology 81 2013 184 192
3. D.S. Goodin, A.T. Reder, and G.C. Ebers Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial Neurology 78 2012 1315 1322
4. M.D. Carrithers Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair Curr Pharm Biotechnol 13 2012 1409 1417
5. J. Zhang, S. Markovic-Plese, and B. Lacet Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis J Exp Med 179 1994 973 984
6. R.C. Axtell, B.A. de Jong, and K. Boniface T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis Nat Med 16 2010 406 412
7. C. Lucchinetti, W. Bruck, and J. Parisi Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 2000 707 717
8. J.M. Frischer, S. Bramow, and A. Dal-Bianco The relation between inflammation and neurodegeneration in multiple sclerosis brains Brain 132 2009 1175 1189
9. D.A. Hafler, A. Compston, and S. Sawcer Risk alleles for multiple sclerosis identified by a genomewide study N Engl J Med 357 2007 851 862
10. P.W. Duda, M.C. Schmied, and S.L. Cook Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis J Clin Invest 105 2000 967 976
11. O. Stuve, N.P. Dooley, and J.H. Uhm Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 Ann Neurol 40 1996 853 863
12. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Neurology 43 1993 655 661
13. L.D. Jacobs, D.L. Cookfair, and R.A. Rudick A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG) Mult Scler 1 1995 118 135
14. H. Panitch, D.S. Goodin, and G. Francis Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial Neurology 59 2002 1496 1506
15. P.A. Calabresi, B.C. Kieseier, and D.L. Arnold Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study Lancet Neurol 13 2014 657 665
16. L.D. Jacobs, R.W. Beck, and J.H. Simon Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 343 2000 898 904
17. G. Comi, M. Filippi, and F. Barkhof Early Treatment of Multiple Sclerosis Study G. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582
18. L. Kappos, C.H. Polman, and M.S. Freedman Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249
19. G. Comi, V. Martinelli, and M. Rodegher Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
20. D. Teitelbaum, A. Meshorer, and T. Hirshfeld Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide Eur J Immunol 1 1971 242 248
21. K.P. Johnson, B.R. Brooks, and J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
22. D.D. Mikol, F. Barkhof, and P. Chang Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 7 2008 903 914
23. M. Filippi, M.A. Rocca, and F. Camesasca Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution Neurology 76 2011 1222 1228
24. A. Gajofatto, P. Bacchetti, and B. Grimes Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Mult Scler 15 2009 50 58
25. R.A. Bermel, X. You, and P. Foulds Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta Ann Neurol 73 2013 95 103
26. I. Casetta, G. Iuliano, and G. Filippini Azathioprine for multiple sclerosis Cochrane Database Syst Rev 2007 CD003982
27. N.H. Litjens, P.H. Nibbering, and A.J. Barrois Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines Br J Dermatol 148 2003 444 451
28. S. Meili-Butz, T. Niermann, and E. Fasler-Kan Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats Eur J Pharmacol 586 2008 251 258
29. R. Gold, L. Kappos, and D.L. Arnold Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
30. R.J. Fox, D.H. Miller, and J.T. Phillips Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 2012 1087 1097
31. B.W. van Oosten, J. Killestein, and F. Barkhof PML in a patient treated with dimethyl fumarate from a compounding pharmacy N Engl J Med 368 2013 1658 1659
32. S. Mandala, R. Hajdu, and J. Bergstrom Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 2002 346 349
33. P.A. Calabresi, E.W. Radue, and D. Goodin Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 545 556
34. P.S. Espinosa, and J.R. Berger Delayed fingolimod-associated asystole Mult Scler 17 2011 1387 1389
35. J.W. Lindsey, K. Haden-Pinneri, N.B. Memon, and L.M. Buja Sudden unexpected death on fingolimod Mult Scler 18 2012 1507 1508
36. R. Nolan, J.M. Gelfand, and A.J. Green Fingolimod treatment in multiple sclerosis leads to increased macular volume Neurology 80 2013 139 144
37. M.A. Zarbin, L.M. Jampol, and R.D. Jager Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis Ophthalmology 120 2013 1432 1439
38. P. OConnor, J.S. Wolinsky, and C. Confavreux Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 2011 1293 1303
39. C. Confavreux, P. OConnor, and G. Comi Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 247 256
40. B.A. Cree Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis Mult Scler 19 2013 835 843
41. T.A. Yednock, C. Cannon, and L.C. Fritz Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 1992 63 66
42. C.H. Polman, P.W. OConnor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
43. R.A. Rudick, D. Miller, and S. Hass Health-related quality of life in multiple sclerosis: effects of natalizumab Ann Neurol 62 2007 335 346
44. N. Putzki, O. Yaldizli, B. Tettenborn, and H.C. Diener Multiple sclerosis associated fatigue during natalizumab treatment J Neurol Sci 285 2009 109 113
45. M.D. Carrithers, I. Visintin, S.J. Kang, and C.A. Janeway Jr Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment Brain 123 2000 1092 1101
46. M.D. Carrithers, I. Visintin, C. Viret, and C.S. Janeway Jr Role of genetic background in P selectin-dependent immune surveillance of the central nervous system J Neuroimmunol 129 2002 51 57
47. W.J. Atwood, K. Amemiya, and R. Traub Interaction of the human polyomavirus, JCV, with human B-lymphocytes Virology 190 1992 716 723
48. R.M Ransohoff Natalizumab and PML Nat Neurosci 8 2005 1275
49. L. Prosperini, C. Gianni, and V. Barletta Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis J Neurol Sci 323 2012 104 112
50. I. Kleiter, K. Hellwig, and A. Berthele Failure of natalizumab to prevent relapses in neuromyelitis optica Arch Neurol 69 2012 239 245
51. E. Wright, K. Rahgozar, and N. Hallworth Epithelial V-like antigen mediates efficacy of anti-alpha(4) integrin treatment in a mouse model of multiple sclerosis PLoS One 8 2013 e70954
52. S.L. Hauser, E. Waubant, and D.L. Arnold B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688
53. F. Aloisi, B. Serafini, and R. Magliozzi Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look Brain 133 2010 e157
54. K. Hawker, P. OConnor, and M.S. Freedman Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial Ann Neurol 66 2009 460 471
55. J. Gossmann, E.H. Scheuermann, and H.G. Kachel Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution Clin Transplant 23 2009 431 434
56. T. Menge, O. Stuve, B.C. Kieseier, and H.P. Hartung Alemtuzumab: The advantages and challenges of a novel therapy in MS Neurology 83 2014 87 97
57. A.J. Coles, C.L. Twyman, and D.L. Arnold Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 2012 1829 1839
58. J.A. Cohen, A.J. Coles, and D.L. Arnold Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 2012 1819 1828
59. D. Bourdette Alemtuzumab and multiple sclerosis: Is it safe? Neurology 83 2014 17 18
60. R.A. Bermel, B. Weinstock-Guttman, and D. Bourdette Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study Mult Scler 16 2010 588 596
61. V. Yadav, D.N. Bourdette, and J.D. Bowen Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study Autoimmune diseases 2012 2012 954739
62. K. Rahgozar, E. Wright, L.M. Carrithers, and M.D. Carrithers Mediation of protection and recovery from experimental autoimmune encephalomyelitis by macrophages expressing the human voltage-gated sodium channel NaV1.5 J Neuropathol Exp Neurol 72 2013 489 504
63. S. Mi, B. Hu, and K. Hahm LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis Nat Med 13 2007 1228 1233
64. I.D. Duncan, W.E. Grever, and S.C. Zhang Repair of myelin disease: strategies and progress in animal models Mol Med Today 3 1997 554 561
65. J.D. Kocsis, Y. Akiyama, K.L. Lankford, and C. Radtke Cell transplantation of peripheral-myelin-forming cells to repair the injured spinal cord J Rehabil Res Dev 39 2002 287 298